Event Date/Time: May 19, 2003 | End Date/Time: May 20, 2003 |
Description
Dr Martin Trang, Vice President & Head, Business Unit Hormone Therapy & Urology, Orion Pharma
Discover the latest research and developments at SMi’s Conference…
Osteoporosis and Menopausal Disorders
19th & 20th May 2003, The Hatton, London
A unique opportunity to learn from leading industry experts including:
Dr Sanjay Kumar, Director, GlaxoSmithKline
Dr Robert Spirtas, Chief, Contraception & Reproductive Health Branch, CPR, NICHD, National Institutes of Health
Dr Donato Agnusdei, Osteoporosis Consultant, Europe & Latin America Eli Lilly
Dr Ji Li, Research Scientist, Amgen
Dr John Fox, Senior Scientist, NPS Pharmaceuticals
Prof Andrea Genazzani, Professor & Chairman, International Society of Gynaecological Endocrinology & University of Pisa
Dr Eugene McCloskey, Clinical Senior Lecturer, Honorary Consultant, Metabolic Bone Diseases, World’s Health Organisation, Collaborating Centre, Metabolic Bone Diseases & University of Sheffield
Key benefits of attending:
DIAGNOSTICS: focus on early detection of osteoporosis
HRT THERAPIES: learn about potential benefits and dangers related to HRT
ALTERNATIVE STRATEGIES: review novel approaches to the treatment of osteoporosis
BONE FORMING AGENTS: understand the use of parathyroid hormone peptides for the treatment of osteoporosis
EXPERIMENTAL AREAS: gain an insight into combination therapies
Day One – 19th May 2003
8.30 Registration & Coffee
9.00 Chairperson’s Opening Remarks
Dr Juliet Compston, Reader, Metabolic Bone Disease & Honorary Consultant Physician, University of Cambridge
KEYNOTE ADDRESS
9.10 Introduction to the endocrinology of the menopause and ageing women
Why is menopause an important issue?
What is the role of endocrinology?
Ways of effectively preventing or managing some of the problems that can be associated with the menopause
How to improve quality of life by preventing the harmful consequences of estrogen hormone deprivation
Overview of future strategies
Prof Andrea Genazzani, Chairman & Professor, International Society of Gynaecological Endocrinology & University of Pisa
THE MENOPAUSE, BONE TURNOVER AND METASTATIC RISK OF PRIMARY BREAST CANCER
9.40 The role of anti-metastatic potential of bisphosphonates
The effects of systematic treatment of breast cancer on bone turnover differ in pre-menopausal women and post-menopausal women
Changes in biochemical markers but not bone mineral density appear to be associates with metastatic risk
The suppression of bone resorption reduces the risk of bone metastases
The incidence of visceral metastases of mortality also appear to be reduced
Dr Eugene McCloskey, Clinical Senior Lecturer & Honorary Consultant, Metabolic Bone Diseases, World’s Health Organisation, Collaborating Centre for Metabolic Bone Diseases & University of Sheffield
DIAGNOSTICS
10.20 Diagnostic test for monitoring osteoporosis
Improving the efficiency of monitoring osteoporosis
The importance of early detection of osteoporosis
Improving screening methods and rates of diagnosis
The difficulties involved in producing diagnostic test, in terms of finance etc
Lessons learned so far
Future strategies
Dr Andy Anderson, Managing Director, Crawford Medical
11.00 Morning Coffee
HRT THERAPIES
ESTABLISHMENT OF RESEARCH AGENDA FOR HRT
11.20 Why is HRT still suggested/requested?
Health risks of E vs E + P
Outcome of NIH meeting
New directions in HRT
Dr Robert Spirtas, Chief, Contraceptive & Reproductive Health Branch, CPR, NICHD, National Institutes of Health
HORMONE REPLACEMENT THERAPIES (HRT)
12.00 Established and potential benefits
Estrogen replacement therapy (ERT)
Where does progestogen fit into therapy?
What is the role of estrogen in the prevention/treatment of osteoporosis?
Androgen therapy
Additional potential benefits of HRT
Dr John Stevenson, Reader & Honorary Consultant Physician, Imperial College London
12.40 Networking Lunch
PHYTO ESTROGENS: THE OTHER HRT?
2.00 Review of studies with natural estrogens in peri and post menopausal women
Menopausal symptom relief
Osteoporosis
Cardivascular system
Endometrium and breast tissue
Dr Terttu Haring, Director, Women’s Health, Kendle
COMBINATION THERAPIES
2.40 Pros and cons
Current combination therapies
Optimisation and improvements in bone mass and bone strength while minimising side effects
Clinical trials of combination of therapeutic agents for osteoporosis
Safety assessment
Effectiveness of combining therapies for osteoporosis
Future strategies for combination therapies
Dr Juliet Compston, Reader, Metabolic Bone Disease & Honorary Consultant Physician, University of Cambridge
3.20 DISCUSSION SESSION
Pros and cons of HRT therapies
Led by:
Dr Juliet Compston, Reader, Metabolic Disease & Honorary Consultant Physician, University of Cambridge & Dr Eugene McCloskey, Consultant, Metabolic Bone Diseases, Women’s Health Organisation & University of Sheffield
4.0 Chairperson’s Closing Remarks followed by Afternoon
Tea
Close of Conference
Day Two - 20th May
8.30 Re-registration & Coffee
9.00 Chairman's Opening Remarks
Prof Andrea Genazzani, Professor & Chairman, International Society of Gynaecological Endocrinology & University of Pisa
MANAGEMENT OF OSTEOPOROSIS AT THE PRIMARY CARE
9.10 Is there a better way of managing osteoporosis?
Osteoporosis – prevalent but neglected
Osteoporosis and other chronic diseases
Physician role in managing osteoporosis
The primary care dignostic tools
Conflicts and proposed resolution
Summary – looking to the future
Dr Irit Yaniv, Vice President, Research & Development, Sunlight Medical
ALTERNATIVE STRATEGIES
NEWER THERAPEUTIC APPROACHES FOR THE TREATMENT OF OSTEOPOROSIS
9.40 New anti-resorptive and anabolic agents
Existing therapies
Need for new therapies
Review of novel anti-resorptives
Review of novel anabolic agents
Future possiblities
Dr Sanjay Kumar, Director, GlaxoSmithKline
NOVEL ANTI-RESORPTIVE THERAPY FOR OSTEOPOROSIS AND OTHER OSTEOLYTIC DISEASES
10.20 Targeting the OPG-RANKL-RANK pathway
Discovery of the signaling pathway
Functional genomics and target validation
Therapeutic targeting strategy
Efficacy in pre-clinical animal models
Early proof-of-concept human clinical data
Dr Ji Li, Research Scientist, Amgen
11.00 Morning Coffee
INTACT PARATHYROID HORMONE 1-84 AS AN ANABOLIC AGENT IN OSTEOPOROSIS
11.20 Does the whole molecule offer advantages over amino-terminal PTH fragments and analogs?
Effects of intact PTH in patients with osteoporosis
Effects of intact PTH on cancellous and cortical bone architecture and strength
Role of carboxyl-terminal PTH fragments in bone
Relevance of osteosarcoma
The potential benefits or adverse consequences of combination (together or sequential) anabolic and antiresorptive therapies
Dr John Fox, Senior Scientist, NPS Pharmaceuticals
BONE FORMING AGENTS: PARATHYROID HORMONE PEPTIDES
12.00 Teriparatide: a new hope for patients with severe osteoporosis
Teriparatide, from bone cracker to bone builder
De novo bone formation after Teriparatide treatment
Effects of Teriparatide on bone architecture
Anti-fracture efficacy of Teriparatide
Combining bone forming and anti-resorptive agents
Future treatment strategies for patients with fractures using Teriparatide
Dr Donato Agnusdei, Osteoporosis Consultant Europe & Latin America, Eli Lilly
12.40 Networking Lunch
OSTEOPOROSIS – STAKEHOLDER INSIGHTS
2.00 Osteoporosis in the US, Japan, Germany, Italy, Spain and the UK
How do diagnosis and treatment rates vary by gender and disease severity across the major pharmaceutical markets?
How do treatment trends vary by disease severity and what really are the leading drugs in practice? Will this still be the case in five years’ time? What are the most important factors influencing physicians treatment practices?
Dominance of the bisphosphonates: how long will Merck’s Fosamax (alendronate) be able to hold onto the market lead? Will P&G/Aventis’ Actonel (risedronate) be its biggest threat, or are there greater dangers in the pipeline?
Can Lilly’s Evista (raloxifene) oust hormone therapy in the postmenopausal population?
What impact will Lilly’s Forteo (Teriparatide) have on treatment patterns? What factors are affecting uptake and are physicians willing to prescribe the drug?
What are the unmet needs in osteoporosis from a physician and patient perspective? What are pharmaceutical companies key strategies for success in this market?
Victoria Williams, Analyst, Datamonitor
VITAMIN D ANALOGS
2.40 2-methylene-19-nor-(20S)-1,25 (OH) 2vitaminD3
How does vitamin D work?
Past successes and failures in osteoporosis treatment
A new class of vitamin D analogs
Unique effect of 2MD in bone
Future plans of 2MD in bone
Dr Lori Plum, Director, Research & Development, Deltanoid Pharmaceuticals
3.20 Afternoon Tea
COMMERCIAL ISSUES
IMPACT OF THE WHI-STUDY ON THE HRT MARKET
3.40 An overview
General recommendations
Concerns
Market trends
Drivers
Outlook
Martin Trang, Vice President & Head, Business Unit Hormone Therapy & Urology, Orion Pharma
IMPACT OF PRODUCT PRESENTATION ON OSTEOPOROSIS MARKET
4.20 Winning in the osteoporosis market by improving presentation of non-oral therapies
Product presentation influencing sales
Development of strategies to maximise user acceptance
Enchancing presentation of inhalation devices
Enchancing the presentation of patches
Enhancing injection devices
Kevin Maynard, Business Development Manager, Imprint Pharmaceuticals
5.00 Chairman's Closing Remarks and Close of Conference